Trevi Therapeutics Q1 2024 net loss $10.9M; cash $72.8M; clinical trials on track

Trevi Therapeutics, Inc.

2024-Q1 EPS reported -$0.11

Net loss of $10.9M vs $6.4M in Q1 2023; R&D expense rose to $8.8M from $5.0M.
Cash, equivalents and marketable securities $72.8M; runway expected into 2026.
Phase 2a RIVER trial in RCC fully enrolled? all sites activated; topline data expected H2 2024.
Phase 2b CORAL trial in IPF chronic cough enrolling ~160 pts; topline data H1 2025.
HAP study 75% enrolled; IND cleared for Phase 1b respiratory physiology trial starting Q3 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Trevi Therapeutics, Inc. reported quarter ended March 31, 2024 results: net income Net loss: For the first quarter of 2024, the Company reported a net loss of $10.9 million, compared to a net loss of $6.. Guidance reaffirmed.

Period: quarter ended March 31, 2024
Net income: Net loss: For the first quarter of 2024, the Company reported a net loss of $10.9 million, compared to a net loss of $6.
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Net loss: For the first quarter of 2024, the Company reported a net loss of $10.9 million, compared to a net loss of $6.4 million in the same period in 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Trevi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-054478

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.